Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Dyne Therapeutics, Inc.NASDAQ: DYN
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity rises 22.9% from a year ago
Total equity stood at $702.15M at the end of Q2 FY2026, up 22.9% from a year earlier and down 18.8% from the prior quarter. Over 3 fiscal years it compounded at +56.8% a year.
Context
- Total equity amounted to 70.6% of total assets at the end of Q2 FY2026, down 7.8 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +22.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 972.13M USD
- Year-over-year change
- +54.3%
- 4-year CAGR
- +27.5%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 972.13M | +54.3% |
| FY2024 | 2024-12-31 | 629.84M | +589.9% |
| FY2023 | 2023-12-31 | 91.29M | -63.8% |
| FY2022 | 2022-12-31 | 252.36M | -31.5% |
| FY2021 | 2021-12-31 | 368.2M | — |
Total Equity vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's Jun 2026 total equity of $702.15M is the 2nd highest of the 11 companies compared; the peer median is $326.42M.
- Its year-over-year change of +22.9% is the 6th highest of 11, against a peer median of +23.5%.
- Total equity amounts to 70.6% of total assets for DYN, versus a peer median of 83.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.51B | +31.7% | +43.6% | 47.3% | |
| Jun 2026 | $702.15M | +22.9% | +56.8% | 70.6% | |
| Mar 2026 | $511.73M | +197.9% | — | 87.7% | |
| Mar 2026 | $394.88M | +12.8% | +24.0% | 89.1% | |
| Sep 2026 | $393.64M | -36.3% | -5.1% | 13.5% | |
| Mar 2026 | $374.13M | +27.1% | -5.3% | 88.5% | |
| Mar 2026 | $278.7M | +118.3% | +196.0% | 85.4% | |
| Mar 2026 | $270.85M | -35.1% | +12.9% | 80.7% | |
| Mar 2026 | $158.03M | +9.5% | -11.0% | 75.8% | |
| Mar 2026 | $133.98M | +45.9% | -6.4% | 85.7% | |
| Jun 2026 | -$165.36M | +19.9% | — | 5.1% | |
| Peer median (excluding DYN) | $326.42M | +23.5% | +3.9% | 83.1% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 200.83M | 172.15M | 121.63M | 435.45M | 893.37M |
| Short-term Investments | 175.75M | 83.87M | 1.47M | 206.82M | 217.19M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 383K | 9.58M | 6.28M | 17.01M | 16.03M |
| Total Current Assets | 382.39M | 265.59M | 129.38M | 659.28M | 1.13B |
| Property, Plant & Equipment (Net) | 40.96M | 38.41M | 33.39M | 30.01M | 44.77M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.31M | 2.32M | 2.32M | 1.94M | 15.6M |
| Total Non-current Assets | 43.27M | 40.73M | 35.71M | 31.96M | 60.37M |
| Total Assets | 425.66M | 306.33M | 165.08M | 691.23M | 1.19B |
| Account Payables | 4.03M | 5.26M | 22.94M | 6.56M | 8.08M |
| Short-term Debt | 0 | 0 | 0 | 4.85M | 5M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 17.75M | 37.55M |
| Total Current Liabilities | 28.72M | 28.09M | 51.1M | 42.26M | 50.63M |
| Long-term Debt | 0 | 0 | 0 | 0 | 15.28M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 148.92M |
| Total Non-current Liabilities | 28.74M | 25.87M | 22.7M | 19.14M | 164.2M |
| Total Liabilities | 57.47M | 53.96M | 73.79M | 61.4M | 214.83M |
| Common Stock | 6K | 6K | 6K | 10K | 16K |
| Retained Earnings | (228.47M) | (396.57M) | (632.51M) | (949.93M) | (1.4B) |
| Accumulated OCI | (269K) | (571K) | 0 | 6K | 475K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 368.2M | 252.36M | 91.29M | 629.84M | 972.13M |
| Total Debt | 32.64M | 30.48M | 27.42M | 23.99M | 20.28M |
| Net Debt | (168.19M) | (141.66M) | (94.21M) | (411.46M) | (873.09M) |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.